Tempest Therapeutics Inc (TPST) Stock Price, Quote & News

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 798 8589

Website: www.tempesttx.com

Address:

2000 Sierra Point Parkway, Suite 400, Brisbane, United States

claybridge Nov. 14 at 9:35 PM

$TPST Taang is out too, but Morgan Stanley held.

1 · Reply

josegodoy Nov. 14 at 9:27 PM

$TPST Pfizer + Metsera (MET) buyout $10 billion deal The crown jewel: MET-097i - a weekly and monthly injectable GLP-1 - about to begin Phase 3 - 2 Other candidates in PI The drama “Metsera initially agreed to be acquired by Pfizer in late September, but just over a month later, Novo shocked the world by offering $6.5 billion upfront for the biotech, outbidding Pfizer’s $4.9 billion upfront offer.” The finale “The total deal value of around $10 billion represents a significant uptick from the $7.3 billion value of the companies' original buyout deal, inked in September.” https://www.fiercebiotech.com/biotech/pfizer-finalizes-metsera-buy-after-contentious-bidding-war-novo-nordisk

0 · Reply

josegodoy Nov. 14 at 6:23 PM

$TPST Sabby Management, LLC has a history of poor investment returns across its portfolios, with a 3-year cumulative return of over -80%. The firm and its principal were also charged by the SEC with abusive naked short selling in 2023.

0 · Reply

Sur1234 Nov. 14 at 5:21 PM

$TPST Sabby sold 276,587 shares in Q3. They were long on this stock; I don't think their reputation matters here. All that matters is big investor exited.

3 · Reply

claybridge Nov. 14 at 4:04 PM

$TPST my bad, the BO price is $221

1 · Reply

We_Like_daStooooock Nov. 14 at 3:45 PM

$TPST Massive aging generation, Big Pharma needs solution for that market...I believe a foreign company may purchase here IMO

0 · Reply

claybridge Nov. 14 at 3:44 PM

$TPST CDTX is now trading well over the $212 all cash BO. Check that board out.

1 · Reply

claybridge Nov. 14 at 3:12 PM

$TPST

0 · Reply

claybridge Nov. 14 at 3:08 PM

$TPST Sabby is gone. I view that as a good thing since Sabby is a notorious short seller.

5 · Reply

dan4100 Nov. 14 at 2:58 PM

$TPST Just want to say I greatly appreciate all the positive and informative posts. I have a lot invested here and it's easy to despair that a BO won't happen with how the stock price has been moving. But thanks to some outstanding work by others, I remain hopeful because the science behind these drugs is real. The assets Tempest holds are absolutely worth multiples higher than the current market cap, there's no disputing that. I can't explain why the market is overlooking this so badly but it really doesn't matter. I believe a strong BO will happen and this will all be worth it.

3 · Reply

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 3 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 11, 2025, 8:00 AM EDT - 5 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

May 13, 2025, 4:28 PM EDT - 6 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:05 PM EDT - 7 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 7 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 27, 2025, 4:10 PM EDT - 8 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 8 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 9 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 10 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:00 AM EST - 11 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

claybridge Nov. 14 at 9:35 PM

$TPST Taang is out too, but Morgan Stanley held.

1 · Reply

josegodoy Nov. 14 at 9:27 PM

0 · Reply

josegodoy Nov. 14 at 6:23 PM

0 · Reply

Sur1234 Nov. 14 at 5:21 PM

$TPST Sabby sold 276,587 shares in Q3. They were long on this stock; I don't think their reputation matters here. All that matters is big investor exited.

3 · Reply

claybridge Nov. 14 at 4:04 PM

$TPST my bad, the BO price is $221

1 · Reply

We_Like_daStooooock Nov. 14 at 3:45 PM

$TPST Massive aging generation, Big Pharma needs solution for that market...I believe a foreign company may purchase here IMO

0 · Reply

claybridge Nov. 14 at 3:44 PM

$TPST CDTX is now trading well over the $212 all cash BO. Check that board out.

1 · Reply

claybridge Nov. 14 at 3:12 PM

$TPST

0 · Reply

claybridge Nov. 14 at 3:08 PM

$TPST Sabby is gone. I view that as a good thing since Sabby is a notorious short seller.

5 · Reply

dan4100 Nov. 14 at 2:58 PM

3 · Reply

claybridge Nov. 14 at 2:56 PM

$TPST Merck BO of CDTX this AM

1 · Reply

Xamayca Nov. 14 at 1:52 PM

$TPST Significant pre market volume hmmm!

0 · Reply

ak123456790 Nov. 14 at 1:34 PM

$TPST I went through MTS’s transaction history for the past five years, and the pattern is very clear. Based on their own “Select Transactions” list, https://www.mtspartners.com/investment-banking/transaction-experience/ 2021 was their weakest year — and 2025 is currently on track to be the second weakest unless they close meaningful Q4 deals. Across the five-year period: MTS averages ~5 transactions in Q4 each year December alone averages ~2 announced transactions Some years (like 2022) show a Q4 surge, with December being a mini-cluster (4 deals) 2023 was an exception — they didn’t post any December transactions, but the year was their strongest in firm history, with nearly $40B in announced deal value, so a quiet December didn’t matter. In contrast, 2025 so far looks thinner, making a strong Q4 (especially November–December) strategically important if they want to avoid a down year relative to their historical averages.

1 · Reply

lousjamsession Nov. 14 at 1:24 PM

$TPST

0 · Reply

ak123456790 Nov. 14 at 9:37 AM

$TPST Someone explain to noswimm that Q4 is historically one of the busiest periods for biotech M&A. Just look at the last few weeks — Merck, Pfizer, Roche, Novo — all of them buying. CDTX was acquired by Merck today. Biotech M&A consistently clusters in Q4 because of well-known corporate mechanics November–mid-December is peak deal season Accounting and tax reasons push big pharma to close before Dec 31 Cash-rich pharma giants are under pressure to deploy capital before budgets reset → internal approvals are faster → budgets are “use it or lose it” → bonuses and KPIs are tied to closing deals Bankers know Q4 is the easiest quarter to close transactions: boards meet more often, CFOs want clean books, and strategic gaps must be filled before the new fiscal year Anyone who works in a bank — like myself — understands how year-end budgeting and capital allocation cycles work. And if you’ve worked around biotech financing it’s even more obvious This isn’t an opinion, it's how corporate finance operate

6 · Reply

GreylockSec Nov. 14 at 2:46 AM

$TPST ...Bingo @nhyujm6 !!! ...GREAT post from the past (which I only had the pleasure of reading today)!...Great modeling here Grant 👊 !! This is exactly why Brady has consisently said Amezallat is a potential "blockbuster"..and, why?... because this mOS is actually highly achievable in your model for a more specific reason...Now that Tempest has discovered via Ph2 that "survival benefit" from the addition of 1120 was maintained in "key subpopulations" including PD-Ll- negative disease, and b-catenin and mutated disease....meaning, the phase 3 can be tweaked/overweighted with additional PD-L1 & b-catenin patients who appear to be way more responsive to 1120 & Tecentriq....And if they achieve 24 months mOS, then even #1 Opdivo +Yervoy gets left in the dust. -Roche has only reached 19.2 months, and they are the SoC... ...24 months mOS for Tempest & Tecentriq would be a straight on Blockbuster 💯 percent....!

6 · Reply

Letsinvest2024 Nov. 14 at 12:35 AM

$TPST while market red and this one green Brady’s friends and family are buying. Nice gift

0 · Reply

backtroid Nov. 14 at 12:23 AM

$TPST crystal balls are gone now diamond balls are here

1 · Reply

GreylockSec Nov. 13 at 11:52 PM

$TPST ... Amazing! Everyone has a real-life crystal ball🔮these days! Any idea where I can get one ? ...Folks, unless you work for MTS at the Managing Partner level, or your Brady's first cousin, there's no way you know anything about the timing of a deal, so, please...

1 · Reply

claybridge Nov. 13 at 11:34 PM

$TPST we're right in the sweet spot. I still wonder what catalyst we might get prior...maybe just a good 'ol fashioned deal leak?

0 · Reply

samson12 Nov. 13 at 11:19 PM

$TPST @YieldYeah I don't think you're a shameless pumper....yet 🤣😉 But on a more serious note, I noticed (from even myself), we seem to take ChatGPT/Gemini/Deepseek views as Gospel. Meaning if those AI platforms think an event will happen, then it WILL likely happen. Which is pretty scary....

1 · Reply

nhyujm6 Nov. 13 at 11:01 PM

$TPST Take a look at this - $285 m for a PhI asset. Also note CVRs - becoming more common in deals....https://www.fiercebiotech.com/biotech/day-one-pens-285m-deal-mersana-and-its-clinical-stage-b7-h4-adc

2 · Reply

Market Cap	38.63M
Revenue (ttm)	0.00
Net Income (ttm)	-41.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,404
Avg Vol	44,990
Day's Range	N/A - N/A
Shares Out	4.44M
Stochastic %K	24%
Beta	-2.20
Analysts	Sell
Price Target	$9.00